FDA approves Pfizer's supplemental new drug application for CIBINQO
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
He is a Chartered Accountant with more than 19 years of extensive experience
Experts’ conclave to pave holistic approach to cancer management
It dwells on colocating 157 nursing colleges with medical colleges and eliminating sickle cell anaemia by 2047
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Subscribe To Our Newsletter & Stay Updated